je.st
news
Tag: asco
Merck to Hold Investor Briefing at 2016 ASCO Annual Meeting
2016-06-01 23:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Dr. Roger M. Perlmutter, president, Merck Research Laboratories, will present an overview of the companys oncology program at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago on June 6, 2016 at 5:45 p.m. CDT (6:45 p.m. EDT). Language: English Contact: MerckMedia:Lainie Keller, (908) 236-5036orInvestor:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: hold
meeting
annual
investor
New KEYTRUDA (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting
2016-05-18 23:19:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate Overall Survival Compared to Ipilimumab, Shows Continued Benefit with Longer Follow-Up KEYNOTE-001 Findings Show Continued Benefit in Response Rates, Duration of Response, and Include New Three-Year Overall Survival Data for KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced final overall survival (OS) data from KEYNOTE-006 and new findings from KEYNOTE-001, including updated response rates, duration of response data and three-year OS data with KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in patients with unresectable or metastatic melanoma. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: including
data
advanced
updated
New KEYTRUDA (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated Overall Survival Data in Non-Small Cell Lung Cancer As Well As Updated Findings in Head and Neck Cancer
2016-05-16 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Data at ASCO Evaluates KEYTRUDA As Single Agent and in Novel Combinations in More Than 15 Different Cancers, Including Several New Tumors KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new and updated data investigating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in more than 15 types of cancer will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3 7, 2016. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558Kim Hamilton, (908) 740-1863orInvestor:Teri Loxam, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
ASCO Sintering Co. Custom Manufacturers New Advanced Shift by Wire Components for the Automotive Industry
2015-09-17 12:31:11| Industrial Newsroom - All News for Today
Effective September 1st 2015 ASCO Sintering Co. will begin supplying a tier 1 automotive supplier with new multiple automotive sintered components used in 2016 MY Shift by Wire technology for effortless gear shifting. The Compound gear, Output Gear, Trigger Arm, Trigger link and couplings are net shape and were...
Tags: the
advanced
industry
automotive
ASCO Sintering Co. Custom Manufacturers New Advanced Shift by Wire Components for the Automotive Industry
2015-09-15 12:31:16| Industrial Newsroom - All News for Today
Effective September 1st 2015 ASCO Sintering Co. will begin supplying a tier 1 automotive supplier with new multiple automotive sintered components used in 2016 MY Shift by Wire technology for effortless gear shifting. The Compound gear, Output Gear, Trigger Arm, Trigger link and couplings are net shape and were...
Tags: the
advanced
industry
automotive
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] next »